NCT02406833 - Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2017

Conditions

Primary Open Angle Glaucoma

Interventions

DRUG

TGF-β2 antisense oligonucleotide

intravitreal injection

PROCEDURE

Trabeculectomy

Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control

Trial Locations (3)

University Hospital Magdeburg, Ophthalmology, Magdeburg

Department of Ophthalmology, Johannes-Gutenberg University Mainz, Mainz

University of Tuebingen, Center of Ophthalmology, Tübingen